Journal
PULMONARY CIRCULATION
Volume 13, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/pul2.12200
Keywords
extracellular matrix; proteoglycan; pulmonary arterial hypertension; synchrotron imaging; vascular disease
Ask authors/readers for more resources
Expansion of extracellular matrix, specifically aggrecan, occurs in all stages of pulmonary angiopathy associated with pulmonary arterial hypertension (PAH). Aggrecan accumulates in the pulmonary arteries of PAH patients and is localized to cellular lesions rather than fibrotic or collagenous lesions. The upregulation of the potential aggrecanase ADAMTS15 in PAH suggests dysregulation of aggrecan turnover is a response to altered hemodynamics. These findings support the potential therapeutic targeting of aggrecan and aggrecanase regulation in PAH.
Expansion of extracellular matrix occurs in all stages of pulmonary angiopathy associated with pulmonary arterial hypertension (PAH). In systemic arteries, dysregulation and accumulation of the large chondroitin-sulfate proteoglycan aggrecan is associated with swelling and disruption of vessel wall homeostasis. Whether aggrecan is present in pulmonary arteries, and its potential roles in PAH, has not been thoroughly investigated. Here, lung tissue from 11 patients with idiopathic PAH was imaged using synchrotron radiation phase-contrast microcomputed tomography (TOMCAT beamline, Swiss Light Source). Immunohistochemistry for aggrecan core protein in subsequently sectioned lung tissue demonstrated accumulation in PAH compared with failed donor lung controls. RNAscope in situ hybridization indicated ACAN expression in vascular endothelium and smooth muscle cells. Based on qualitative histological analysis, aggrecan localizes to cellular, rather than fibrotic or collagenous, lesions. Interestingly, ADAMTS15, a potential aggrecanase, was upregulated in pulmonary arteries in PAH. Aligning traditional histological analysis with three-dimensional renderings of pulmonary arteries from synchrotron imaging identified aggrecan in lumen-reducing lesions containing loose, cell-rich connective tissue, at sites of intrapulmonary bronchopulmonary shunting, and at sites of presumed elevated pulmonary blood pressure. Our findings suggest that ACAN expression may be an early response to injury in pulmonary angiopathy and supports recent work showing that dysregulation of aggrecan turnover is a hallmark of arterial adaptations to altered hemodynamics. Whether cause or effect, aggrecan and aggrecanase regulation in PAH are potential therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available